Virtual surgical planning-assisted versus free-hand head and neck reconstruction: Systematic review, meta-analysis, and a novel classification.

J Craniomaxillofac SurgAug 5, 2026 (epub)
Clinical ResearchPlastic SurgeryGeneral Surgery

Christos Perisanidis, Julio Acero, Rui Fernandes et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the clinical outcomes of virtual surgical planning (VSP)-assisted versus free-hand (FH) techniques in head and neck reconstruction, involving 2763 patients across 42 studies. VSP significantly reduced operative time by 64.75 minutes and ischemia time by 37.40 minutes, while also lowering the odds of bony non-union and malocclusion.

Key findings

  • VSP reduced operative time by 64.75 minutes compared to FH techniques.
  • Ischemia time was significantly lower by 37.40 minutes with VSP.
  • VSP was associated with lower odds of bony non-union (OR 0.31).
  • Malocclusion odds were significantly reduced with VSP (OR 0.14).

Why it matters

The findings suggest that VSP-assisted reconstruction may enhance surgical efficiency and patient outcomes in head and neck procedures, potentially leading to shorter recovery times and fewer complications.

Source

PubMed · PMID 42570605

Published in J Craniomaxillofac Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Plastic Surgery

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.